Results 171 to 180 of about 36,390 (302)

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

Allergy, EarlyView.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, Sara C. Hamon, Jennifer Maloney, Jamie M. Orengo, Zhen Chen, Stephanie Amato Ricci, Bolanle Akinlade, Aris Baras, Gary Herman, Brandy L. Bennett, George D. Yancopoulos   +19 more
wiley   +1 more source

Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma. [PDF]

Front Immunol
Miguéns-Suárez P, Martelo-Vidal L, Vázquez-Mera S, Blanco-Aparicio M, Calvo-Álvarez U, González-Fernández C, Mosteiro-Añón M, Corbacho-Abelaira D, Hermida-Valverde T, Calvo-Henríquez C, Nieto-Fontarigo JJ, Salgado FJ, González-Barcala FJ.   +12 more
europepmc   +1 more source

MAIT Cells Suppress IgE‐Mediated Asthma via IFNγ‐Dependent B Cell Regulation

Allergy, EarlyView.
In this study, we demonstrate that MAIT cell antagonism during sensitization and challenge with HDM worsens the development of airway hyperreactivity without effects on type 2 or 17 associated cytokine production or lung inflammation. Rather, MAIT cells appear to regulate HDM‐induced asthma through direct inhibition of IgE production.
Angela M. Cannata, Jaclyn W. McAlees, Julie M. Hargis, Archana Shankar, Shouxiong Huang, Senad Divanovic, Ian P. Lewkowich   +6 more
wiley   +1 more source

S100P mediates IL-13/ATF4-driven epithelial barrier dysfunction in eosinophilic asthma: a potential biomarker and therapeutic target. [PDF]

J Transl Med
Li D, Yin Y, Hao R, Ren Y, Gu S, Wang H, Han L, Ye S, Li L, Yao X, Zeng X.   +10 more
europepmc   +1 more source

Non-eosinophilic asthma: mechanisms and treatment

Asthma causes a unique type of inflammation in the airways. Until recently, the cell responsible for this inflammation was thought to be the eosinophil.

core  

Preventive Application of House Dust Mite‐Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children

Allergy, EarlyView.
HDM‐pSLIT induced IgG, IgG1, and IgG4 specific to major HDM allergens in sensitized non‐allergic preschool children without increasing HDM‐sIgE. It blunted the development of new sensitizations and reduced HDM reactivity in skin and basophils. HDM‐pSLIT treated children displayed a blocking effect on HDM‐induced basophil activation.
Varsha Dwivedi, Klara Schmidthaler, Hilal Demir, Justyna Sieber, René Gaupmann, Livia Mia Gona‐Höpler, Christina Bannert, Saskia Gruber, Eleonora Dehlink, Thomas Eiwegger, Alexandra Graf, Barbara Bohle, Zsolt Szépfalusi   +12 more
wiley   +1 more source

Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Li Y, Li J, Yang H, Wu L.
europepmc   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma. [PDF]

Sci Rep
Xinmin P, Jinxia C, Fengyuan L.
europepmc   +1 more source

Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma. [PDF]

Antibodies (Basel)
Walsh GM.
europepmc   +1 more source